Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

68.20 +2.00 (+3.02%)
Streaming Delayed Price Updated: 11:27 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Halozyme (HALO) Q3 2025 Earnings Call Transcript
Halozyme (HALO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Insights into Halozyme Therapeutics's Upcoming Earnings
 
Via Benzinga
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method
Halozyme Therapeutics shows strong growth metrics, including soaring earnings, sales, and a high ROE, fitting a proven growth investing strategy. 
Via Chartmill
Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million
Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million 
Via The Motley Fool
Topics Cannabis
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup
Halozyme Therapeutics (HALO) offers a high-growth momentum play with strong earnings, rising profit margins, and a technical breakout setup for potential entry. 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Outlook For Halozyme Therapeutics
 
Via Benzinga
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case
Halozyme Therapeutics (HALO) is a strong value stock with high profitability, a healthy balance sheet, and solid growth, all while trading at an attractive valuation. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile
Halozyme Therapeutics offers strong growth and profitability at an attractive valuation. Its ENHANZE drug delivery tech drives revenue, with a low P/E ratio for an affordable growth stock. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout
Halozyme Therapeutics offers strong growth with high profitability and a positive technical setup, making it a compelling biotech stock to watch. 
Via Chartmill
The Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts
 
Via Benzinga
Halozyme Therapeutics Inc (NASDAQ:HALO) Demonstrates Strong Growth and Profitability
Discover Halozyme Therapeutics, a top growth stock with strong earnings, soaring revenue, and high profitability. A prime example of the Navellier investing method. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Prime Candidate for Affordable Growth
Halozyme Therapeutics (HALO) offers strong growth, high profitability, and an attractive valuation, making it a compelling GARP (Growth at a Reasonable Price) investment candidate. 
Via Chartmill
Forecasting The Future: 7 Analyst Projections For Halozyme Therapeutics
 
Via Benzinga
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity
Halozyme Therapeutics is a high-growth biotech stock with strong earnings, revenue momentum, and a bullish technical setup nearing a breakout. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Navellier's Growth Investing Principles
Discover Halozyme (HALO), a top growth stock with strong earnings surprises, soaring revenue, and exceptional profitability, fitting Navellier's proven investment strategy. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors
Halozyme (HALO) presents a strong value investing case with low P/E ratios, robust financial health, high profitability, and solid growth, suggesting it trades below its intrinsic value. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum
Halozyme Therapeutics (HALO) exemplifies Mark Minervini's Trend Template, combining a strong technical uptrend with accelerating earnings growth and expanding profit margins. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals
Discover HALOZYME (HALO), an affordable growth stock with strong profitability, solid financials, and a reasonable valuation. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen
HALOZYME (HALO) exemplifies Louis Navellier's growth investing strategy with strong sales growth, soaring earnings, high ROE, and consistent positive earnings surprises. 
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out as a Top Undervalued Stock with Strong Fundamentals
Discover HALOZYME (HALO), a top value investing pick. It boasts a strong Valuation Rating of 9, high profitability, and robust growth, making it a fundamentally sound yet undervalued stock. 
Via Chartmill
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors
HALOZYME THERAPEUTICS (HALO) offers affordable growth with strong revenue, EPS expansion, and undervalued metrics, blending value and growth investing principles. 
Via Chartmill
What Does the Market Think About Halozyme Therapeutics?
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Fits Louis Navellier’s High-Growth Stock Criteria
Louis Navellier’s *The Little Book That Makes You Rich* outlines 8 key factors for identifying high-growth stocks like HALOZYME THERAPEUTICS (HALO), which excels in earnings, sales, margins, and ROE.... 
Via Chartmill
Halozyme (HALO) Q2 EPS Jumps 69%
Via The Motley Fool
Topics Intellectual Property
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Technical Breakout Potential
HALOZYME THERAPEUTICS INC (HALO) shows strong earnings growth, rising profit margins, and bullish technicals, making it a high-growth momentum stock to watch. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.